The treatment of paclitaxel or cisplatin resistant ovarian cancer cells with a glutaminase inhibitor increased their sensitivity to chemotherapy through inhibiting cell proliferation, regardless of their glutamine dependence status [23]. This evidence concerns the gene GLS and ovarian cancer.